peptide dosing FAQ

Complete the current single-peptide protocol to its planned endpoint before introducing a second compound. Peptide research relies on isolating variables. Adding a new peptide halfway through an existing protocol makes it impossible to attribute observed effects to either compound. If you're 4 weeks into an 8-week BPC-157 protocol and want to add CJC-1295/Ipamorelin, finish the remaining 4 weeks of BPC-157, take a 1-week washout, then begin the two-peptide stack as a new protocol with fresh baseline measurements. The only exception is if the single-peptide protocol is clearly producing no observable effects after 6+ weeks at therapeutic dose. In that case, discontinue, document the null result, and transition to a different compound or stack.

Do not inject crystallised peptide solution. Crystallisation indicates either improper storage temperature (exposure above 8°C), contamination during reconstitution (non-sterile bacteriostatic water or improper vial handling), or a formulation incompatibility (incorrect pH of the reconstitution solution). Discard the vial entirely. Lyophilised peptides should produce a clear or slightly opalescent solution when reconstituted with bacteriostatic water at neutral pH. If crystallisation occurs consistently across multiple vials from the same supplier, the issue is likely the peptide formulation itself. Lyophilised peptides require specific excipients (mannitol, trehalose) to maintain stability in solution. Source replacement peptides from a supplier that provides Certificates of Analysis documenting reconstitution stability testing, like Real Peptides.

Stop the current protocol immediately and recalculate your reconstitution math from scratch using the formula: total peptide amount (mg) ÷ volume added (mL) = concentration (mg/mL). Compare your intended dose to what you actually administered based on the correct concentration. If you exceeded the target dose by less than 50%, the primary risk is temporary receptor desensitisation. Most peptides tolerate moderate overdosing without irreversible effects. Document the error, adjust your reconstitution for the next vial, and resume at the correct dose after a 48–72 hour washout period. If you exceeded the target by more than 100%, consult the peptide's safety data sheet for adverse event thresholds and monitor for compound-specific side effects (e.g., water retention with growth hormone secretagogues, gastrointestinal distress with BPC-157 overdose).

Use it, but accept the waste. Attempting to extend usability beyond 28 days compromises results. Reconstitute the full 10mg vial with 5–10mL bacteriostatic water (1–2mg/mL concentration) and dose normally for 28 days. Discard the remainder on day 29 even if peptide remains. The alternative. Using degraded peptide for weeks 5–10. Introduces a confounding variable (declining potency) that invalidates dose-response data. For future orders, calculate 28-day consumption and choose vip vial size accordingly. If budget constraints require using the oversized vial across multiple months, consider splitting the lyophilised powder into smaller aliquots before reconstitution and storing unreconstituted aliquots at −20°C. But this requires sterile technique and appropriate workspace to avoid contamination.

Halve your consumption calculation. A 50mcg dose administered every other day requires 50mcg × 3.5 doses per week × 4 weeks = 700mcg (0.7mg) over 28 days. A 1mg vial becomes appropriate, with minimal waste. Lower injection frequency reduces contamination risk because the vial undergoes fewer septum punctures. 14 total over 28 days instead of 28. This extends the practical contamination-free window slightly but doesn't change the peptide stability timeline. VIP still degrades by day 29 regardless of how many times the vial was accessed. Researchers using intermittent dosing schedules benefit from smaller vial sizes because waste percentage drops when total consumption decreases.

Use a medical-grade peptide cooler that maintains 2–8°C without ice contact. Insulin cooling cases like the FRIO wallet use evaporative cooling and maintain refrigeration temperature for 36–48 hours without electricity. Adequate for most transport scenarios. VIP tolerates brief temperature excursions (under 2 hours at 15–20°C) without catastrophic degradation, but every hour above 8°C reduces remaining shelf life. If transport exceeds 48 hours, consider whether it's more cost-effective to discard the partial vial and reconstitute a new one at the destination rather than risk transporting a vial that may have experienced undetectable temperature excursions during transit.

Recalculate concentration immediately using the actual volume added, not the intended volume. If you meant to add 2mL but added 3mL to a 5mg vial, your concentration is now 1,667mcg/mL instead of 2,500mcg/mL. To deliver 250mcg, you'll need 15 units instead of 10. Write the corrected concentration on the vial label and use it for all subsequent dosing calculations. The peptide itself is unaffected. Only the concentration has changed. Do not attempt to 'correct' by withdrawing water from the vial; bacteriostatic water and peptide are already mixed homogeneously, and partial removal creates unpredictable concentration gradients inside the vial.

Your reconstituted concentration is too dilute for the dose you need. Example: 1,000mcg/mL concentration requires 60 units (0.6mL) to deliver 600mcg, but your syringe maxes out at 50 units. Solutions: reconstitute a new vial at higher concentration (use less water), or split the dose into two injections of 30 units each. Splitting is acceptable for research protocols where injection site doesn't affect absorption, but introduces variability in exact dose timing. The better approach is forward planning. Calculate maximum required dose before reconstitution and choose water volume accordingly so all doses fit within a single 0.5mL or 1.0mL syringe draw.

Convert milligrams to micrograms by multiplying by 1,000 before starting any calculation. If a protocol calls for 1.5mg of Tesofensine, that's 1,500mcg. Then apply the standard formula: 1,500mcg ÷ concentration (mcg/mL) = volume in mL. Mixing units mid-calculation is the most common source of tenfold dosing errors. Always express peptide mass in micrograms and volume in millilitres throughout the entire calculation sequence. Only convert to syringe units as the final step.